RSS-Feed abonnieren
DOI: 10.1055/s-2001-14106
Klinische Wirkungen und Pharmakodynamik der Insulinanaloga Lispro, Aspart und Glargin
Clinical efficacy and pharmacodynamics of the insulin analogs lispro, aspart and glarginPublikationsverlauf
Publikationsdatum:
31. Dezember 2001 (online)

Subkutane Injektion der bisher üblichen Insulinpräparationen ermöglicht keine optimale Imitation des endogenen Insulinsekretionsmusters, da subkutan injiziertes Normalinsulin einen zu langsamen Wirkbeginn und eine zu lange Wirkdauer (bis zu 12 h bei Verwendung hoher Dosen) aufweist [Abb. 1] [30]. Das als Verzögerungsinsulin verwendete NPH-Insulin weist nicht den gewünschten niedrigen und konstanten metabolischen Effekt über die Zeit auf, sondern eine ausgeprägte maximale Wirkung nach ca. 6 h, mit einem konstanten Absinken der Wirkung in der Zeit danach [Abb. 1] [36]. Unter anderem deshalb gelingt es vielen Diabetes-Patienten nicht, eine gute Stoffwechselkontrolle zu etablieren [5] [7] [9] .
Literatur
- 1
Anderson J H, Brunelle R L, Keohane P. et al .
Mealtime treatment with insulin analogue
improves postprandial hyperglycemia and hypoglycemia in NIDDM patients.
Arch
Intern Med.
1997;
157
1249-1255
MissingFormLabel
- 2
Anderson J H, Brunelle R L, Koivisto V. et al .
Improved mealtime treatment of diabetes
mellitus using insulin analogue.
Clin Ther.
1997;
19
62-72
MissingFormLabel
- 3
Anderson J H, Brunelle R L, Koivisto V A, Pfützner A, Trautmann M E, Vignati L, DiMarchi R. and the Multicenter Insulin Lispro Study Group .
Reduction
of postprandial hyperglycemia and frequency of hypoglycemia in IDDM
patients on insulin-analog treatment.
Diabetes.
1997;
46
265-270
MissingFormLabel
- 4
Bahr M, Kolter T, Seipke G, Eckel J.
Growth
promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin
(HOE 901) in muscle cells.
Eur J Pharmacol.
1997;
320
259-265
MissingFormLabel
- 5
Berger M.
Towards
more physiological insulin therapy in the 1990 s. A comment.
Diabetes
Res Clin Pract.
1989;
6
S25-S31
MissingFormLabel
- 6
Berger M.
Safety
of insulin glargine.
Lancet.
2000;
356
2013-2014
MissingFormLabel
- 7
Berger M, Heinemann L.
Are
presently available insulin analogues clinically beneficial?.
Diabetologia.
1997;
40
S91-S96
(Suppl 2))
MissingFormLabel
- 8
Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring H U.
The
long acting human insulin analog HOE 901: characteristics of insulin
signalling in comparison to Asp(B10) and regular insulin.
Horm
Metab Res.
1998;
30
123-129
MissingFormLabel
- 9
Bolli G B, Di Marchi R D, Park G D, Pramming S, Koivisto V A.
Insulin analogues
and their potential in the management of diabetes mellitus.
Diabetologia.
1999;
42
1151-1167,
MissingFormLabel
- 10
Bolli G B, Owens D R.
Insulin glargine.
Lancet.
2000;
356
443-445
MissingFormLabel
- 11
Bott S, Bott U, Berger M, Mühlhauser I.
Intensified
insulin therapy and the risk of severe hypoglycaemia.
Diabetologia.
1997;
40
926-932
MissingFormLabel
- 12
Bott U, Ebrahim S, Hirschberger S, Leukel P, Sieber H J.
Effect of the insulin
analogue insulin aspart on quality-of-life and treatment satisfaction
in type 1 diabetic patients.
Diabetologia.
1999;
42
A237
(Suppl 1)
MissingFormLabel
- 13
Bott U, Mühlhauser I, Overmann H, Berger M.
Validation
of a diabetic-specific quality-of-life scale for patients with type
1 diabetes.
Diabetes Care.
1998;
21
757-769
MissingFormLabel
- 14
Brange J, Owens D R, Kang S, Volund A.
Monomeric insulins and their
experimental and clinical implications.
Diabetes Care.
1990;
13
923-954
MissingFormLabel
- 15
Brange J, Ribel U, Hansen J F, Dodson G, Hansen M T, Havelund S, Melberg S G, Norris F, Norris K, Snel L. et al .
Monomeric
insulins obtained by protein engineering and their medical implications.
Nature.
1988;
333
679-682
MissingFormLabel
- 16
Brunelle R L, Llewelyn J, Anderson J H, Gale E A, Koivisto V.
Meta-analysis
of the effect of insulin lispro on severe hypoglycemia in patients
with type 1 diabetes.
Diabetes Care.
1998;
21
1726-1731
MissingFormLabel
- 17
Brunner G A, Hirschberger S, Sendlhofer G. et al .
Post-prandial administration of the insulin
analogue insulin aspart in patients with Type 1 diabetes mellitus.
Diabet
Med.
2000;
17
371-375
MissingFormLabel
- 18
Chantelau E.
Evidence
that upregulation of serum IGF-1 concentration can trigger acceleration
of diabetic retinopathy.
Br J Ophthalmol.
1998;
82
725-730
MissingFormLabel
- 19
Chantelau E, Kohner E M.
Why some cases
of retinopathy worsen when diabetic control improves.
BMJ.
1997;
315
1105-1106
MissingFormLabel
- 20
Ciofetta M, Lalli C, Del S indaco
P. et al .
Contribution of postprandial versus
interprandial blood glucose to HbA1c in type 1 diabetes on physiologic
intensive therapy with lispro insulin at mealtime.
Diabetes
Care.
1999;
22
795-800
MissingFormLabel
- 21
Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B.
Improvement of blood
glucose control in type 1 diabetic patients treated with lispro
and multipe NPH injections.
Diabetic Med.
1999;
16
319-324
MissingFormLabel
- 22
Ebeling P, Jansson P A, Smith U, Lalli C, Bolli G, Koivisto V.
Strategies toward
improved control during insulin lispro therapy in IDDM.
Diabetes
Care.
1997;
20
1287-1289
MissingFormLabel
- 23
Gale E A. The UK Trial Group .
A randomized, controlled trial
comparing insulin lispro with human soluble insulin in patients
with Type 1 diabetes on intensified insulin therapy.
Diabet
Med.
2000;
17
209-214
MissingFormLabel
- 24
Garg S K, Carmain J A, Braddy K C, Anderson J H, Vignati L, Jennings M K, Chase H P.
Pre-meal
insulin analogue insulin lispro vs. Humulin R insulin treatment
in young subjects with type 1 diabetes.
Diabetic Med.
1996;
13
47-52
MissingFormLabel
- 25
G lazer N B, Zalani S, Anderson J H, Bastyr E J.
Safety of insulin
lispro: pooled data from clinical trials.
Am J Health
Syst Pharm.
1999;
56
542-547
MissingFormLabel
- 26
Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber J P. The Study Group
for the Development of Pump Therapy in Diabetes .
Comparison
of continuous subcutaneous insulin infusion and multiple daily injection
regimens using insulin lispro in type 1 diabetic patients on intensified
treatment: a randomized study.
Diabetes Care.
2000;
23
1232-1235
MissingFormLabel
- 27
Hansen B F, Danielsen G, Drejer K, Sorensen A R, Wiberg F C, Klein H H, Lundemose A G.
Sustained
signalling from the insulin receptor after stimulation with insulin
analogues exhibiting increased mitogenic potency.
Biochem
J.
1996;
315
271-279
MissingFormLabel
- 28
Heinemann L.
Hypoglycemia
and insulin analogues: is there a reduction in the incidence?.
J
Diabetes Complications.
1999;
13
105-114
MissingFormLabel
- 29
Heinemann L, Breuer J, Cebulla D, Wüssel B, Bender R, Heise T.
Wirkungsprofile von Normalinsulin,
NPH-Insulin sowie einer 25/75-Mischung hergestellt aus
gentechnologischem bzw. semisynthetischem Humaninsulin.
Diabetes
u Stoffw.
1996;
5
157-163
MissingFormLabel
- 30
Heinemann L, Heise T, Jorgensen L N, Starke A AR.
Action profile
of the rapid acting insulin analogue B28Asp.
Diabetic
Med.
1993;
10
535-539
MissingFormLabel
- 31
Heinemann L, Heise T, Wahl C h, Trautmann M E, Ampudia J, Starke A AR, Berger M.
Prandial
glycaemia after a carbohydrate-rich meal in type I diabetic patients
using the rapid acting insulin analogue [Lys(B28), Pro(B29)].
Diabetic
Med.
1996;
13
625-629
MissingFormLabel
- 32
Heinemann L, Kapitza C, Starke A AR, Heise T.
Time-action profile of
the insulin analogue B28Asp.
Diabetic Med.
1996;
13
683-684
MissingFormLabel
- 33
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T.
Time-action profile of
the long-acting insulin analog insulin glargine (HOE901) in comparison
with those of NPH insulin and placebo.
Diabetes Care.
2000;
23
644-649
MissingFormLabel
- 34
Heinemann L, Weyer C, Rauhaus M, Heinrichs J, Heise T.
Variability of
the metabolic effect of soluble insulin and the rapid acting insulin
analogue insulin aspart.
Diabetes Care.
1998;
21
1910-1914
MissingFormLabel
- 35
Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L.
No evidence
for accumulation of HOE901 after multiple injections in type 1 diabetic
patients.
Diabetologia.
2000;
43
A196
(Suppl 1)
MissingFormLabel
- 36
Heise T, Weyer C, Serwas A, Heinrichs J, Osinga J, Roach P, Woodworth J R, Gudat U, Heinemann L.
Time-action
profiles of novel premixed preparations of insulin lispro and NPL
insulin.
Diabetes Care.
1998;
21
800-803
MissingFormLabel
- 37
Heller S R, Amiel S A, Mansell P. U.K. Lispro Study Group .
Effect of the fast-acting
insulin analog lispro on the risk of nocturnal hypoglycemia during
intensified insulin therapy.
Diabetes Care.
1999;
22
1607-1611
MissingFormLabel
- 38
Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J, . The Benelux-UK
insulin lispro study group .
Reduced frequency of severe
hypoglycemia and coma in well-controlled IDDM patients treated with
insulin lispro.
Diabetes Care.
1997;
20
1827-1832
MissingFormLabel
- 39
Home P D.
Rapid-acting
insulin analogues: when randomized clinical trial results do not
help.
Diabet Med.
2000;
17
6-8
(Suppl 2)
MissingFormLabel
- 40
Home P D, Lindholm A, Hylleberg B, Round P, . for the U.K.Insulin Aspart
Study Group .
Improved glycemic control with insulin
aspart.
Diabetes Care.
1998;
21
1904-1909
MissingFormLabel
- 41
Home P D, Lindholm A, Riis A.
Insulin
aspart vs. human insulin in the management of long-term blood glucose
control in Type 1 diabetes mellitus: a randomized controlled trial.
Diabetic
Med.
2000;
17
762-770
MissingFormLabel
- 42 Jorgensen L N, Dideriksen L H. Preclinical
studies of rapid-acting insulin analogues. Thieme Verlag In:
Frontiers in Insulin Pharmacology, Berger M, Gries FA (eds) 1993: 110-117
MissingFormLabel
- 43
Jörgens V, Grüsser M, Bott U, Mühlhauser I, Berger M.
Effective
and safe translation of intensified insulin therapy to general internal medicine
departments.
Diabetologia.
1993;
36
99-105
MissingFormLabel
- 44
Kang S, Brange J, Burch A, Volund A, Owens D R.
Subcutaneous
insulin absorption explained by insulin’s physicochemical
properties. Evidence from absorption studies of soluble human insulin and
insulin analogues in humans.
Diabetes Care.
1991;
14
942-948
MissingFormLabel
- 45
Kellerer M, Häring H U.
Insulin
analogues: impact of cell model characteristics on results and conclusions
regarding mitogenic properties.
Exp Clin Endocrinol Diabetes.
2001;
109
63-64
MissingFormLabel
- 46
Kotsanos J G, Vignati L, Huster W. et al .
Health-related quality-of-life results
from multinational clinical trials of insulin lispro.
Diabetes
Care.
1997;
20
948-958
MissingFormLabel
- 47
Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T.
Correlations
of receptor binding and metabolic and mitogenic potencies of insulin
analogs designed for clinical use.
Diabetes.
2000;
49
999-1005
MissingFormLabel
- 48
Lalli C, Ciofetta M, Del Sindaco P. et al .
Long-term
intensive treatment of type 1 diabetes with the short-acting insulin
analogue lispro in variable combination with NPH insulin at mealtime.
Diabetes
Care.
1999;
22
468-477
MissingFormLabel
- 49
Lepore M, Pampanelli S, Fanelli C. et al .
Pharmacokinetics and pharmacodynamics of
subcutaneous injection of long- acting human insulin analog glargine,
NPH insulin, and ultralente human insulin and continuous subcutaneous
infusion of insulin lispro.
Diabetes.
2000;
49
2142-2148
MissingFormLabel
- 50
Lindholm A
, Andersen H F, Hylleberg B
, Gall M A.
A review of the safety profile of insulin aspart.
Diabetologia.
2000;
43 (Suppl 1)
A199
MissingFormLabel
- 51
Melki V, Renard E, Lassmann V ague V. et al .
Improvement
of HbA1c and blood glucose stability in IDDM patients treated with
lispro insulin analog in external pumps.
Diabetes Care.
1998;
21
977-982
MissingFormLabel
- 52
Nathan D N.
Long-term
complications of diabetes mellitus.
N Engl J Med.
1993;
328
1676-1685
MissingFormLabel
- 53
Pampanelli S, Torlone E, Lalli C. et al .
Improved postprandial metabolic control
after subcutaneous injection of a short acting insulin analog in
IDDM of short duration with residual pancreatic-cell function.
Diabetes
Care.
1995;
18
1452-1459
MissingFormLabel
- 54
Pieber T R, Eugene-Jolchine I, Derobert E, . the European Study Group of HOE901 in Type 1 diabetes .
Efficacy
and safety of HOE901 versus NPH insulin in patients with type 1
diabetes.
Diabetes Care.
2000;
23
157-162
MissingFormLabel
- 55
Raskin P, Guthrie R A, Leiter L, Riis A, Jovanovic L.
Use
of insulin aspart, a fast-acting insulin analog, as the mealtime
insulin in the management of patients with type 1 diabetes.
Diabetes
Care.
2000;
23
583-588
MissingFormLabel
- 56
Raskin P, Klaff L, Bergenstal R, Halle J P, Donley D, Mecca T.
A 16-week comparison of
the novel insulin analog insulin glargine (HOE 901) and NPH human
insulin used with insulin lispro in patients with type 1 diabetes.
Diabetes
Care.
2000;
23
1666-1671
MissingFormLabel
- 57
Ratner R E, Hirsch I B, Neifing J L, Garg S K, Mecca T E, Wilson C A. U.S. Study Group
of Insulin Glargine in Type 1 Diabetes .
Less hypoglycemia
with insulin glargine in intensive insulin therapy for type 1 diabetes.
Diabetes
Care.
2000;
23
639-643
MissingFormLabel
- 58
Rave K, Sawicki P T, Heise T, Heinemann L.
Pharmacodynamic
properties of insulin in patients with and without diabetic nephropathy.
Diabetes.
2000;
49
A76
MissingFormLabel
- 59
Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. German Humalog-CSII Study
Group .
Use of insulin lispro in continuous subcutaneous
insulin infusion treatment. Results of a multicenter trial.
Diabetes
Care.
1999;
22
784-788
MissingFormLabel
- 60
Reviriego J, Millan M.
Health-related quality
of life and insulin lispro. A naturalistic approach.
Diabetes
Care.
1998;
21
1203-1204
MissingFormLabel
- 61
Rosenstock J, Park G, Zimmerman J. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator
Group .
Basal insulin glargine (HOE 901) versus NPH
insulin in patients with type 1 diabetes on multiple daily insulin
regimens.
Diabetes Care.
2000;
23
1137-1142
MissingFormLabel
- 62
Rowe R, Anderson J H, Gale E.
A double-blind comparison
of insulin lispro and regular insulin in patients on a multiple
injection regimen.
Diabetes.
1996;
45
71A
(Suppl 2)
MissingFormLabel
- 63
Schmitt H, Symanowski S M, Holleman F, Rees A, Rottiers R, Anderson J H.
Comparison
of pre-meal therapy with insulin lispo and regular insulin in patients
with IDDM.
Diabetologia.
1996;
39
A221
(Suppl 1)
MissingFormLabel
- 64
Scholtz H E, van Niekerk N, Meyer B H, Rosenkranz B.
An assessment of
the variability in the pharmacodynamics (glucose lowering effect)
of HOE901 compared to NPH and ultralente human insulins using the
euglycaemic clamp technique.
Diabetologia.
1999;
42
A235
(Suppl 1)
MissingFormLabel
- 65
UK Prospective Diabetes Study
Group .
Intensive blood-glucose control with sulphonylureas
or insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837-853
MissingFormLabel
- 66
Yki-Jarvinen H, Dressler A, Ziemen M. HOE 901/3002 Study Group .
Less nocturnal
hypoglycemia and better post-dinner glucose control with bedtime
insulin glargine compared with bedtime NPH insulin during insulin
combination therapy in type 2 diabetes.
Diabetes Care.
2000;
23
1130-1136
MissingFormLabel
- 67
Zinman B, Tildesly H, Chiasson J L, Tsui E, Strack T.
Insulin
lispro in CSII: results of a double-blind cross-over study.
Diabetes.
1997;
46
440-443
MissingFormLabel
Korrespondenz
PD Dr. Lutz Heinemann
Profil Institut für Stoffwechselforschung
GmbH
Stresemannallee 6
41460 Neuss
Telefon: 02131/155402
Fax: 02131/155 409
eMail: Lutz.Heinemann@profil-research.de